Shanghai Medicilon Inc.

  On July 4 th , the 2024 International Pharmaceutical Services Industry Innovation and Development Conference, along with the 9 th   Summit for China Pharmaceutical R&D Innovation, was grandly held at the Xiongan Convention and Exhibition Center.  At the conference, the highly anticipated "2024 China Pharmaceutical R&D Strength Ranking" was announced.  Shanghai Medicilon Inc. (Medicilon) stood out among hundreds of pharmaceutical enterprises and was honored with the " Top 20 Chinese R&D CRO Enterprises in 2024" award. About the Top 20 Chinese R&D CRO Enterprises in 2024 The "2024 China Pharmaceutical R&D Strength Ranking" is selected by the Organizing Committee of the China Pharmaceutical R&D Innovation Summit and the Expert Committee of the 2024 China Pharmaceutical R&D Strength Ranking. It aims to uncover and drive innovative forces in pharmaceutical R&D, encourage and recognize enterprises making significant contributio...

  Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research. After this appointment, Dr. Zhang will further promote Medicilon to enter the CDMO field, help Medicilon to establish a large-scale production base in line with GMP standards through strategic cooperation, self-construction or merger and acquisition, further improve the crystal research service platform, strengthen the construction of technical platform in the field of small nucleic acid drugs and polypeptide drug preparations, and help Medicilon achieve "CRO+CDMO" two-wheel drive. At the same time, Dr. Zhang will also further promote the business development of Medicilon and help Medicilon to research and develop new drugs. Dr. Rui Zhang, Ph.D., University of Victoria, Postdoc at the School of Pharmacy, University of Manitoba, has been deeply involved in the field of drug research and development for 15 years. He...

  Lonza ranks first, and China's WuXi department (WuXi AppTec + WuXi Biologics) has ranked the second position in the world. Among the top 10, two Asian companies and European companies occupy the majority. 2021 Global CDMO Ranking Top 10 Rank Name Country Revenue(billions of dollars) growth rate(%) 1 Lonza Switzerland 4.810 12.5% 2 Wuxi China 3.389 31.78% 3 Catalent USA 3.094 22.9% 4 FAREVA SA France 2.137 - 5 Recipharm AB Sweden 1.303 30% 6 Samsung Bio Korea 1.034 14.5% 7 Delpharm France 0.945 - 8 Siegfried Sweden 0.913 1.40% 9 Boehringer Ingelheim Germany 0.905 5.6% 10 Aenova Group Germany 0.857 0.55% In terms of growth rate, WuXi ranks first. In terms of revenue scale, there is still a gap of nearly 1.5 billion US dollars between WuXi and Lonza. Global CDMO Enterprise Ranking There are some non-listed companies abroad whose financial data are not regularly disclosed, but their strength cannot be ignored. There are not many CDMO heads in China, and most of them have a revenue of...

  Drug metabolism refers to the chemical change process of drugs in the body. Most drugs lose their activity after being metabolized, and are converted into extremely high water-soluble metabolites, which are beneficial to excretion from the body. There are also some drugs that are hardly metabolized in the body and are excreted as original drugs.   For more details, please read  Factors Affecting Pharmacokinetics of Drugs . The metabolism of drugs requires the participation of enzymes. The liver is an important organ for drug metabolism. The cytochrome P-450 enzyme system of liver microsomes is the main enzyme system that promotes drug metabolism, so it is called liver drug enzymes. Some drugs can also be decomposed by related enzymes in other tissues. The availability and content of liver drug enzymes are not unstable, and individual differences are large, and they are easily affected by certain drugs. Any drug that can enhance the activity of liver drug enzymes or acce...

  On September 10, 2020, the “2020 China Pharmaceutical and Health Industry Development Conference and the 4th China Pharmaceutical R&D Innovation Summit (PDI)” announced the “2020 China   Top 20 R&D CRO Companies ” (hereinafter referred to as “R&D CRO List”). Since 2015, the domestic pharmaceutical industry policy reform has accelerated, especially after my country joined ICH in 2017, domestic pharmaceutical companies have accelerated the transformation and upgrading from generic drugs to the combination of generic drugs. The demand side of domestic and foreign outsourcing services is accelerating, and the dividends of innovation and upgrading in the domestic pharmaceutical market are gradually emerging. Some traditional offshore outsourcing companies have begun to attach importance to the expansion of domestic business, and the proportion of onshore outsourcing business in the overall business structure has begun to increase.        ...

  Medicilon is the first CRO to offer preclinical animal testing service for the global pharmaceutical companies in China. We provide the   IND application  for the preclinical services. Medicilon is the CRO that fulfill both the China and US GLP standards. Medicilon could submit the application for both US FDA and CFDA for your new drug. Since 2004, we have successfully helped our clients to submit their new drug application to US FDA and CFDA and met the requirements of the US FDA and CFDA. We have undergone several inspections and passed all of them. Medicilon will provide an efficient, cost-effective and professional service to help our clients to achieve their goals. Medicilon’s IND Application Service With an insight into drug regulatory policy environment of China and the United States, Medicilon’s drug registration is able to provide CFDA IND application, USFDA IND / ANDA application services for domestic customers and CFDA IND / ANDA application service for forei...